Schizophrenia: FDA approves novel antipsychotic without extrapyramidal side effects
Silver Spring – For the first time, the US Food and Drug Administration (FDA) has approved a drug for the treatment of schizophrenia that does not bind directly to dopamine receptors. The drug Cobenfy (KarXT)